Together, these findings suggest that DAP10/12-based CAR-T cells could overcome expansion and exhaustion challenges while enhancing antitumor responses in B-cell lymphoma while curbing immune evasion by antigen loss. This evidence concerns the gene HCST and B-cell non-Hodgkin lymphoma.